CVS Health Corporation $CVS Shares Sold by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd lowered its position in CVS Health Corporation (NYSE:CVS) by 1.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 90,197 shares of the pharmacy operator’s stock after selling 1,480 shares during the period. UniSuper Management Pty Ltd’s holdings in CVS Health were worth $6,111,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. CoreCap Advisors LLC grew its holdings in CVS Health by 18.6% during the 4th quarter. CoreCap Advisors LLC now owns 4,328 shares of the pharmacy operator’s stock valued at $194,000 after buying an additional 679 shares during the last quarter. Gotham Asset Management LLC grew its holdings in CVS Health by 119.3% during the 4th quarter. Gotham Asset Management LLC now owns 230,533 shares of the pharmacy operator’s stock valued at $10,349,000 after buying an additional 125,434 shares during the last quarter. Humankind Investments LLC grew its holdings in CVS Health by 13.5% during the 4th quarter. Humankind Investments LLC now owns 13,655 shares of the pharmacy operator’s stock valued at $613,000 after buying an additional 1,621 shares during the last quarter. Janus Henderson Group PLC grew its holdings in CVS Health by 0.6% during the 4th quarter. Janus Henderson Group PLC now owns 765,186 shares of the pharmacy operator’s stock valued at $34,352,000 after buying an additional 4,283 shares during the last quarter. Finally, Invenomic Capital Management LP acquired a new stake in CVS Health during the 4th quarter valued at $2,540,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

CVS stock opened at $73.76 on Monday. CVS Health Corporation has a 52-week low of $43.56 and a 52-week high of $74.53. The stock’s fifty day simple moving average is $66.60 and its 200-day simple moving average is $66.00. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $93.56 billion, a price-to-earnings ratio of 20.60, a price-to-earnings-growth ratio of 0.81 and a beta of 0.62.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.35. The business had revenue of $98.92 billion for the quarter, compared to analysts’ expectations of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business’s revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Tuesday, July 22nd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.6%. The ex-dividend date of this dividend was Tuesday, July 22nd. CVS Health’s dividend payout ratio (DPR) is 74.30%.

Wall Street Analyst Weigh In

CVS has been the topic of a number of analyst reports. Jefferies Financial Group increased their target price on CVS Health from $74.00 to $80.00 and gave the company a “buy” rating in a report on Monday, June 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $78.00 target price on shares of CVS Health in a report on Tuesday, August 26th. Truist Financial increased their target price on CVS Health from $82.00 to $84.00 and gave the company a “buy” rating in a report on Monday, May 12th. Cowen reiterated a “buy” rating on shares of CVS Health in a report on Monday, August 4th. Finally, Bernstein Bank decreased their price objective on CVS Health from $78.00 to $72.00 and set a “market perform” rating on the stock in a report on Wednesday, July 16th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, CVS Health presently has a consensus rating of “Buy” and a consensus target price of $77.89.

Insider Buying and Selling at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the transaction, the director directly owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. This trade represents a 25.29% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.22% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.